FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Carhartt Inc., one of America’s leading manufacturers of durable workwear and…
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients…
Announces next steps for clinical development plan in severe liver diseasesBOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:…
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),…
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON, Aug. 15, 2023 (GLOBE…
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023…
ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on…
Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new…
Greenville, South Carolina, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) a leading US-based…
VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"),…